cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects

A compound that accumulates in cells more readily than a commonly used colorectal cancer drug may be just as useful in treating colorectal tumors, but with fewer side effects. Both compounds are analogues of cisplatin, a potent anticancer agent, but the newly investigated compound, known as cDPCP, may better target colorectal cells, potentially sparing other body tissues from damage.

Professor Stephen J. Lippard is the Senior author of the above mentioned paper that was published in the online edition of the Proceedings of the National Academy of Sciences on July 1. Other authors of the paper are Katherine Lovejoy, co-lead author of the paper (Lippard Group), Michael McCormick, (just graduated from the Lippard Group), Ryan C. Todd (Lippard Group), Shuzhong Zhang and Kathleen Giacomini of the University of California at San Francisco, J. Alejandro D'Aquino of Brandeis University, and Joyce Reardon and Aziz Sancar of the University of North Carolina School of Medicine.

See MIT News Story
To read PNAS publication